定量CT在进展性肺纤维化中的预后价值与尼达尼布疗效:INBUILD试验亚组分析
该研究基于INBUILD试验中474例进展性肺纤维化患者的亚组数据,评估UCLA和e-Lung算法定量CT指标的预后价值及尼达尼布对指标的影响。结果显示基线定量CT评分越高,FVC下降越快、52周内FVC下降≥10%或死亡风险越高;尼达尼布在24周和52周显著减缓QILD评分和e-Lung TDE的恶化。
要点
- 基线定量CT评分高者52周FVC下降更快、进展或死亡风险更高。
- 尼达尼布24周时QILD评分和e-Lung TDE相对安慰剂分别降低7%和8%。
- 定量CT可作为进展性肺纤维化临床试验中评估药物疗效的敏感指标。
核心结论
- 定量CT方法可辅助预测进展性肺纤维化患者的疾病进展并评估药物在临床试验中的疗效。
研究设计与样本
- INBUILD试验(双盲、随机、安慰剂对照)的亚组研究,纳入474例进展性肺纤维化患者,评估UCLA定量ILD和肺纤维化评分、e-Lung总病变范围、网状血管评分及加权网状血管评分与ILD进展的关联。
主要发现
- 安慰剂组中,基线定量CT评分越高,52周内FVC年下降量(mL/年)越大。
- 基线定量CT评分高于中位数者,52周内FVC占预计值下降≥10%或死亡的风险高于低于中位数者,限制性平均生存时间差异为40-65天。
- 尼达尼布对24周QILD评分和e-Lung TDE变化有显著影响,相对安慰剂差异分别为-7%(95%CI:-11,-2;p=0.005)和-8%(95%CI:-12,-4;p<0.001)。
- 尼达尼布对52周QILD评分和e-Lung TDE变化均有显著影响,相对安慰剂差异均为-7%(95%CI:-12,-2;p<0.05)。
临床怎么用
- 在进展性肺纤维化患者的临床试验中,可采用定量CT指标作为预测疾病进展和评估药物疗效的补充工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Change in forced vital capacity (FVC) is an established endpoint in clinical trials in lung fibrosis, but more sensitive measures of structural deterioration are needed. Quantitative computed tomography (QCT) measurements predict FVC decline and mortality, but more information is needed on their prognostic value and response to therapy. OBJECTIVES: Evaluate the prognostic potential of quantitative CT measurements derived using University of California Los Angeles (UCLA) and e-Lung (Brainomix) algorithms, and effects of nintedanib on these measurements, in patients with progressive pulmonary fibrosis (PPF). METHODS: Among patients with PPF in a sub-study of the INBUILD trial (N = 474), associations between UCLA quantitative ILD and lung fibrosis (QILD and QLF) scores, e-Lung total disease extent (TDE), reticulovascular score (RVS), and weighted RVS, and ILD progression were assessed. MEASUREMENTS AND MAIN RESULTS: In the placebo group, higher baseline QCT scores were associated with a greater rate of decline in FVC (mL/year) over 52 weeks. The risk of decline in FVC % predicted ≥10% or death over 52 weeks was greater with QCT scores above vs below the median; differences in restricted mean survival time ranged from 40-65 days. Nintedanib had significant effects on changes in QILD score and e-Lung TDE at week 24 (relative difference versus placebo [%]: -7 [95% CI: -11, -2; p = 0.005] and -8 [-12, -4; p < 0.001], respectively) and week 52 (-7 [-12, -2; p < 0.05] for both). CONCLUSIONS: Quantitative CT methods can facilitate prediction of progression and assessment of the efficacy of drugs in clinical trials in patients with PPF.
引用
- Devaraj A, George PM, Joly O, et al. Quantitative Computed Tomography in Progressive Pulmonary Fibrosis: Data from a Sub-Study of the Double Blind, Randomized, Placebo-controlled INBUILD Trial. Am J Respir Crit Care Med. 2026. PMID: 42809243. doi:10.1093/ajrccm/aamag526
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。